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A B S T R A C T
Despite emerging new therapeutic opportunities, cancer is still a major health problem and a leading cause of
death worldwide. Breast tumors are the most frequently diagnosed female malignancies, and the triple-negative
subtype is associated with poorer prognosis and lower survival rates than other breast cancer types. The aims of
the present study were to determine the anticancer potency of a set of C-3 and C-16 modiﬁed estradiol-deri-
vatives against a panel of breast cancer cell lines, and to characterize the mechanism of action of two selected
compounds (1 and 5) against the MDA-MB-231 triple-negative breast cancer cell line. Growth-inhibitory
properties were investigated by an MTT-assay. Cell cycle analysis by ﬂow cytometry has revealed G1 phase
accumulation and indicated the proapoptotic eﬀect of 1 and 5 through the elevation of the apoptotic subG1
phase on MDA-MB-231 cells after 24 h treatment. The antimetastatic activities of these compounds were ex-
amined by wound healing and Boyden chamber assays, and both compounds were shown to signiﬁcantly inhibit
the migration and invasion of MDA-MB-231 cells at sub-antiproliferative concentrations. Gelatin zymography
assay has indicated that matrix metalloproteinase-2 and -9 are not involved in the antimetastatic action of the
molecules. Western blot analysis was performed with 24 h incubation to examine the possible changes in the
level of focal adhesion kinase (FAK), and both compounds were found to inhibit the phosphorylation of FAK in a
concentration-dependent manner in MDA-MB-231 cells. The results of this study demonstrate that C-3 and C-16
modiﬁed estradiol derivatives are potent antiproliferative and antimetastatic compounds against a triple-ne-
gative breast cancer cell line with a mechanism of action involving the inhibition of FAK, a novel anticancer
therapeutic target. Therefore, these ﬁndings can be utilized in the development of promising anticancer agents
with steroid skeleton.
1. Introduction
Cancer is a crucial cause of morbidity and mortality worldwide,
with the incidence of malignant diseases rising both in highly devel-
oped and less developed countries. In 2012, 14.1 million new patients
and 8.2 million cancer-related deaths were estimated globally, and>
3.14 million new cancer cases were diagnosed in Europe. Amongst
women, the most common cancer type is breast cancer, characterized
by the highest incidence and mortality rates, comprising 25% of all
diagnosed cancer cases and causing 15% of all cancer-related deaths
(Steliarova-Foucher et al., 2015; Torre et al., 2015).
Triple-negative breast cancer (TNBC) is a subtype of breast tumors
described by the downregulation of estrogen receptor (ER), proges-
terone receptor (PR) and human epidermal growth factor receptor 2
(HER2). Approximately 15–20% of all breast cancers are triple-negative
tumors, and this subtype is responsible for 25% of breast cancer-related
deaths (Lee and Djamgoz, 2018). TNBC patients are typically
5–10 years younger than other breast cancer patients at the time of
diagnosis (Newman et al., 2015). Indicators for the aggressive behavior
of TNBC include a high recurrence rate and faster metastatic spread,
leading to poorer prognosis amongst all breast cancer subtypes. Re-
garding recurrence, the secondary tumor usually occurs within 5 years
from the initial diagnosis, with the brain and viscera being aﬀected
more often than in case of non-TNBC primaries which usually cause
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metastasis to bone. Compared to other subtypes, TNBC has a shorter
median time to death (4.2 vs. 6 years) and worse overall survival. Both
of these basic triple-negative features and the possible molecular di-
versity within TNBCs hamper the development of targeted therapies.
Although several novel pharmacological groups of drugs, like poly
(ADP-ribose) polymerase inhibitors and immunotherapeutic agents
have shown promising results in clinical trials, developing speciﬁed
treatment for TNBC is still an urgent unmet medical need (Lee and
Djamgoz, 2018; Lin et al., 2008).
Estrogens have an essential inﬂuence on the evolution of re-
productive processes. Furthermore, they play a role in the development
of hormone-dependent tumors of the reproductive organs, such as
breast, ovarian, endometrial, uterine and prostate cancers (Ascenzi
et al., 2006; Chen et al., 2008; Nelles et al., 2011; Pearce and Jordan,
2004). Although the proliferation-stimulating activity of 17β-estradiol
is well-established, numerous studies have also investigated the antic-
ancer potential of structurally modiﬁed estrogen derivatives (Bodnár
et al., 2016; Cadot et al., 2007; Cushman et al., 1997; Jourdan et al.,
2011; Mernyák et al., 2014; Mernyák et al., 2015; Möller et al., 2009;
Szabó et al., 2016).
A fundamental requirement for estrane-based anticancer drug can-
didates is the lack of their hormonal activity. Certain structural mod-
iﬁcations, such as substitution at C-2 or C-3 of the estrane skeleton lead
to the loss of the estrogenic properties of the compounds (Anstead et al.,
1997; Cushman et al., 1997; Wölﬂing et al., 2003). Additionally,
modiﬁcation of the D-ring of the estrange skeleton leading to D-homo
and D-seco derivatives results complete loss of estrogenic activity
(Jovanovic-Santa et al., 2003; Jovanovic-Santa et al., 2015). Moreover,
some of such agents may additionally interact with the enzyme ar-
omatase (CYP1A19) indicating a secondary way of intervention in the
estrogen-dependent proliferative disorders including gynecological
cancers, endometriosis (Trifunovic et al., 2017).
In a previous study, the binding abilities of possible isomers of 16-
hydroxymethyl-3,17-estradiol to estrogen receptor were investigated by
radioligand-binding assay, utilizing receptor protein prepared from
rabbit uteri. The relative binding aﬃnities (RBA) of each estradiol de-
rivative was lower than 2.0% of that of estradiol, indicating that the
introduction of a 16-hydroxymethyl group abolishes the aﬃnity in-
dependently of its conﬁguration (Tapolcsányi et al., 2002). Conse-
quently, the presence of a hydroxymethylene group at C-16 is detri-
mental concerning the estrogenic activity of the tested compounds.
Based on these preliminary ﬁndings, it can be stated that the 16-hy-
droxymethylene-3,17-estradiol core might be suitable for the design of
biologically active estrone derivatives lacking hormonal activity.
We have recently reported that the presence of a 3-benzyl ether
function on the estrane core may enhance the antiproliferative potential
of the steroid (Mernyák et al., 2014; Mernyák et al., 2015). In order to
combine the structural moieties responsible for an increase in the an-
tiproliferative and a decrease in the estrogenic actions, here we have
synthesized additional 3-benzyl ethers bearing electronically diﬀerent
substituents at the 4′-position.
The aim of the current investigation was to characterize the antic-
ancer properties of these 16-hydroxymethyl-estradiol analogs on a
panel of breast cancer cell lines in vitro. The most promising agents
were selected for further analyses in order to describe the mechanism of
the action against the MDA-MB-231 triple-negative breast cancer cell
line. Although the hormonal receptor status of the utilized cell lines was
diﬀerent we aimed to describe hormone-independent antiproliferative
properties. The eﬀects of the selected molecules on cancer cell migra-
tion were also evaluated.
2. Materials and methods
2.1. Chemicals
The four possible stereoisomers of 3-benzyloxy-16-hydro-
xymethylene-estra-1,3,5(10)-trien-17-ol (1–4) were synthesized and
characterized as reported previously (Tapolcsányi et al., 2002). Three
further analogs with a substituted benzyl function at C-3 have also been
prepared (5–7). The synthesis and chemical characterization of the
molecules are available as Supplementary material (Fig. 1).
2.2. Cell cultures
Human breast cancer cell lines, including MCF7, T47D, MDA-MB-
231 and MDA-MB-361, as well as non-cancerous ﬁbroblasts (MRC-5)
were purchased from the European Collection of Authenticated Cell
Cultures (ECACC, Salisbury, UK). All cell lines were maintained in
minimal essential medium (MEM) supplemented with 10% fetal bovine
serum, 1% non-essential amino acids and 1% antibiotic-antimycotic
mixture, and were stored in humidiﬁed air containing 5% CO2 at 37 °C.
All utilized components were obtained from Lonza Group Ltd. (Basel,
Switzerland).
2.3. Determination of antiproliferative activities
To determine the antiproliferative action of the tested compounds
against four malignant breast cancer cell lines (MCF-7, T47D, MDA-MB-
231 and MDA-MB-361), an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyltetrazolium bromide) assay was carried out. Cells were seeded at
a density of 5000 cells/well into 96-well plates (in the case of MDA-MB-
361 10,000 cells/well), treated with increasing concentrations of 16-
Fig. 1. Chemical structures of the synthesized and investigated estradiol analogs.
I. Sinka et al. European Journal of Pharmaceutical Sciences 123 (2018) 362–370
363
hydroxymethyl-estranes (0.1–30.0 μM) under cell culturing conditions
for 72 h. At the end of incubation, 5mg/ml MTT solution was added to
the samples. Precipitated formazan crystals were solubilized in di-
methyl sulfoxide and absorbance was measured at 545 nm with a mi-
croplate reader. Wells containing untreated cells were used as control
(Mosmann, 1983).
Based on these results, sigmoidal dose-response curves were ﬁtted
and IC50 values were calculated using GraphPad Prism 5.01 (GraphPad
Software, San Diego, CA, USA). The growth-inhibitory eﬀects of the
tested compounds were compared to cisplatin (Ebewe Pharma GmbH,
Unterach, Austria) in the same concentration range. MRC-5 human ﬁ-
broblasts were also examined by the same method to verify the se-
lectivity of the test compounds towards cancer.
2.4. Cell cycle analysis by ﬂow cytometry
Cellular DNA content was determined by ﬂow cytometry. MDA-MB-
231 cells were seeded into 6-well plates at a density of
250,000–300,000 cells/well. After 24 h incubation cells were washed
with phosphate-buﬀered saline (PBS) and gathered with trypsin. The
samples were centrifuged at 1500 rpm for 10min, additionally washed
and centrifuged again, and ﬁxed in 1ml of 70% ethanol,−20 °C, for at
least 30min. The dye solution (0.1 mg/ml PI, 0.003 μl/ml Triton-X,
0.02mg/ml RNase A, and 1.0 mg/ml sodium citrate dissolved in dis-
tilled water) was then added to the samples for 60min. The cell cycle
analysis was carried out by a Partec CyFlow instrument (Partec GmbH,
Münster, Germany). In all measurements, 20,000 cells were analyzed.
The percentages of cells in diﬀerent cell cycle phases (subG1, G1, S and
G2/M) were determined by the ModFit LT software (Verity Software
House, Topsham, ME, USA). The subG1 fraction was considered as the
apoptotic cell population (Vermes et al., 2000).
2.5. Wound healing assay
The action of the selected compounds on cell migration was assessed
by a wound healing assay. The assay was performed with speciﬁc
wound assay chambers (ibidi GmbH, Martinsried, Germany). MDA-MB-
231 cells were trypsinized and 25,000 cells were seeded into each
chamber of the inserts. After an overnight incubation for appropriate
cell attachment at 37 °C under 5% CO2, the culture insert was removed.
A washing step with PBS was performed to remove non-adherent cells
and debris. Cells were treated with increasing concentrations of each
test compound in a medium containing 2% FBS for 24 h. Migration of
the cells to the wound site was visualized by a phase-contrast inverted
microscope (Axiovert 40, Zeiss, Thornwood, NY, US). Images were
taken by a CCD camera at planned intervals to assess wound closure.
The rate of migration was calculated as the ratio of wound closure in
treated samples after 24 h and 0 h, respectively, as compared with the
ratio of the wound closure in untreated control samples after 24 h and
0 h, respectively (Bózsity et al., 2017).
2.6. Boyden chamber assay
Invasion ability of MDA-MB-231 cells was investigated by a BD
BioCoat Matrigel Invasion Chamber (BD Biosciences, Bedford, MA,
USA) containing an 8 μm pore size PET membrane and a thin layer of
matrigel basement matrix. Fifty thousand cells were suspended in
serum-free medium and were injected into the top insert before the
tested compounds were added in sub-antiproliferative concentrations.
A medium containing 10% FBS was used as chemoattractant in the
bottom well. The inserts were removed after incubation for 24 h at
37 °C under 5% CO2 and the upper surface of the membrane was
cleaned from non-invading cells with a cotton swab. After a washing
step with PBS, the insert was ﬁxed with cold 100% methanol, washed
with PBS again and stained with crystal violet solution. The invading
and stained cells were counted under a phase-contrast inverted
microscope. To determine the rate of invasion, the number of treated
samples and untreated controls were counted and compared to each
other.
2.7. Gelatin zymography assay
A gelatin zymography assay was utilized to determine how the test
compounds aﬀect the activities of matrix metalloprotease-2 (MMP-2)
and −9 (Snoek-van Beurden and Von den Hoﬀ, 2005). MDA-MB-231
cells were seeded in experimental dishes at approximately 80% con-
ﬂuency and were allowed to grow overnight. After a washing step with
PBS the test compounds were added in serum-free medium and in-
cubated for 24 h. Then the supernatant containing the secreted MMP-2
and MMP-9 enzymes were collected from above the cells and was
centrifuged at 6000 rpm at 4 °C for 2min, then collected again. Equal
amounts of the samples mixed with bromophenol blue dye in 5:1 ratio
were separated by SDS-PAGE containing 0.1% gelatin via electrophor-
esis at 120 V for 90min. Major forms of MMPs were identiﬁed by Prism
Ultra Protein Ladder molecular size marker (Abcam Cambridge, U.K.).
The gel was washed twice by 2.5% Triton X-100 solution, then treated
with the reaction solution containing 50mM Tris-HCl (pH 7.5), 150mM
NaCl and 5mM CaCl2. After incubation for 24 h the gel was stained
with Coomassie brilliant blue G-250 (SimplyBlue™ Safestain, Thermo
Fisher Scientiﬁc, Waltham, MA, USA) for 60min and washed by dis-
tilled water twice. Finally, the gel was captured by a Luminescent
Image Analyzer System (LAS 4000 mini, Fujiﬁlm, Tokyo, Japan).
2.8. Western blot assay
A Western Blot assay was performed to evaluate the antimetastatic
properties of the examined compounds. Two million cells were seeded
in small experimental dishes, and the tested compounds were added in
medium containing 2% FBS the next day. Cells were detached from the
dishes by a rubber policeman and centrifuged at 7000 rpm, 4 °C for
2min, washed with PBS and centrifuged again. Whole cell extracts
(WCEs) were prepared by re-suspending cells in TEGN lysis buﬀer
(10mM Tris pH 7.5, 1 mM EDTA, 420mM NaCl, 10% glycerol and 0.5%
NP40) supplemented with 1mM DTT and a cocktail of protease and
phosphatase inhibitor (Roche Applied Science, Penzberg, Germany).
After 10min on ice and centrifugation (13,000 rpm, 4 °C, 10min) the
protein content of the supernatant was mixed with bromophenol blue
dye in 2:1 ratio. Equal amounts of WCEs were ﬁrst separated by SDS-
PAGE with electrophoresis for 1 h at 160 V, transferred onto ni-
trocellulose membranes for overnight at 20 V, 4 °C. Afterwards, the
samples were blocked and incubated with a primary antibody followed
by an appropriate secondary antibody. The antibodies utilized were
FAK pY397 (Becton Dickinson, Franklin Lakes, NJ, USA), FAK (Cell
Signaling Technology, Danvers, MA, USA), β-actin (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) and GAPDH (Cell Signaling
Technology). Blots were visualized by enhanced chemiluminescence
(ECL-Plus, GE Healthcare Life Sciences, Little Chalfont, UK) using a
Luminescent Image Analyzer System.
2.9. Statistical analysis
GraphPad Prism 5.01 was used for the statistical evaluation of
measured data in each experiment. To determine statistical sig-
niﬁcance, one-way ANOVA with Dunnett post-test for comparison of
multiple groups was utilized. A p value < 0.05 was regarded as sta-
tistically signiﬁcant.
3. Results
3.1. Antiproliferative activity of the tested compounds
Several 16-hydroxymethyl-estranes proved to be potent
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antiproliferative agents against various breast cancer cell lines. The
calculated IC50 values representing their growth-inhibitory eﬀects are
presented in Table 1. As shown by our results, the conﬁguration of the
substituents at positions 16 and 17 play a limited role in the agents'
antiproliferative properties. On the other hand, substituents, especially
the p-methoxy group on the benzyl function at C-3 may enhance the
anticancer potency. The compounds were additionally tested against
the non-cancerous MRC-5 cells in order to obtain data concerning their
selectivity towards cancer. In this regard, our compounds were not
selective towards cancer cells but they were comparable to the re-
ference agent cisplatin. Based on these results the analog with the
lowest IC50 value (5) and its related, unsubstituted analog (1) were
selected for additional investigations.
3.2. Cell cycle analysis by ﬂow cytometry
In order to characterize the mechanism of action of the selected
compounds against the MDA-MB-231 cell line, ﬂow cytometry was
carried out and the cell cycle phase distributions were analyzed after
24 h of incubation. The applied concentrations were determined based
on the calculated IC50 values. Both compounds elicited a signiﬁcant and
concentration-dependent increase of the cell population in the G1
phase, on the expense of the reduction of those in the G2/M phase
(Fig. 2). In spite of its substantially higher calculated IC50 1 elicited
remarkable cell cycle disturbance even at 5 μM. Additionally, 1 and 5
induced a modest but signiﬁcant elevation of the hypodiploid (subG1)
cell population at all the applied concentrations indicating the proa-
poptotic potential of these compounds.
3.3. Wound healing assay
As another means of investigating the anticancer activity of the
tested estradiol derivatives, the possible motility inhibiting properties
were examined by a wound healing assay. Migration of untreated MDA-
MB-231 cells within the wound of the chambers was considered as
100% after 24 h incubation. Treatment with 1 and 5 signiﬁcantly re-
duced the movement ability of MDA-MB-231 cells even at sub-anti-
proliferative concentrations (Fig. 3).
3.4. Boyden chamber assay
Besides the anti-migratory eﬀect, the inﬂuence on the invasion
Table 1
Antiproliferative eﬀects of the tested compounds (1–7) on human breast cancer cell lines and MRC-5.
Growth inhibition (%) ± SEM
[calculated IC50 value (μM)a]
MDA-MB-231 MCF7 T47D MDA-MB-361 MRC-5
1 10 μM 31.52 ± 1.82 60.16 ± 1.56 54.49 ± 0.27 93.07 ± 0.52 78.02 ± 2.63
30 μM 94.90 ± 0.46 97.20 ± 0.41 89.95 ± 043 93.25 ± 1.09 96.50 ± 0.20
IC50 (μM) 12.70 8.15 8.41 4.60 6.73
2 10 μM 93.82 ± 0.49 91.54 ± 0.56 82.73 ± 1.63 93.80 ± 0.70 94.78 ± 0.49
30 μM 96.21 ± 0.34 97.83 ± 0.24 82.10 ± 0.50 93.98 ± 0.26 96.88 ± 0.21
IC50 (μM) 3.91 5.05 4.58 3.81 5.53
3 10 μM 76.41 ± 0.65 27.02 ± 1.28 38.76 ± 2.02 62.73 ± 2.20 39.10 ± 3.23
30 μM 92.17 ± 0.59 88.57 ± 1.23 90.29 ± 0.58 86.15 ± 0.93 92.63 ± 0.15
IC50 (μM) 5.93 13.57 15.73 7.21 10.20
4 10 μM 84.34 ± 1.22 56.64 ± 2.23 47.49 ± 2.41 79.06 ± 2.70 53.67 ± 3.39
30 μM 92.79 ± 0.26 86.85 ± 0.89 94.56 ± 0.73 89.85 ± 1.02 76.84 ± 2.19
IC50 (μM) 5.47 9.05 10.44 5.38 7.33
5 10 μM 89.54 ± 0.82 96.46 ± 0.65 95.58 ± 0.26 81.08 ± 1.77 76.50 ± 2.28
30 μM 87.73 ± 0.32 96.68 ± 0.17 95.26 ± 0.90 86.97 ± 1.26 79.75 ± 0.95
IC50 (μM) 4.59 3.45 2.75 1.26 6.67
6 10 μM 61.13 ± 2.35 72.68 ± 0.79 80.22 ± 2.10 76.84 ± 1.24 61.03 ± 2.82
30 μM 82.84 ± 0.92 89.08 ± 0.94 87.03 ± 1.45 81.08 ± 1.72 78.09 ± 1.79
IC50 (μM) 7.48 4.24 2.98 4.65 1.46
7 10 μM 30.94 ± 2.42 39.34 ± 0.86 34.70 ± 1.42 n.d. n.d.
30 μM 68.82 ± 1.68 57.70 ± 0.75 52.69 ± 3.13
IC50 (μM) n.d. n.d. n.d.
Cisplatin 10 μM 20.84 ± 0.81 53.03 ± 2.29 51.00 ± 2.02 67.51 ± 1.01 60.25 ± 3.31
30 μM 74.47 ± 1.20 86.90 ± 1.24 57.95 ± 1.45 87.75 ± 1.10 61.92 ± 1.01
IC50 (μM) 19.13 5.78 9.78 3.74 6.19
n.d.: not determined.
a IC50 values were calculated from two experiments with 5 parallel wells if the growth inhibition of the compound was> 75% at 30 μM.
Fig. 2. Eﬀects of compounds 1 and 5 on the MDA-MB-231 cell cycle after incubation for 24 h. Results are mean values ± SEM from three measurements. *, ** and
*** indicates p < 0.05, p < 0.01 and p < 0.001 as compared t with the control cells, respectively.
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capacity of tumor cells is another important descriptor of the anti-
metastatic property. The Matrigel Matrix-coated membrane (8.0 μm
pore diameter) in Boyden chambers allows invasive cells to cross the
membrane while it blocks the migration of non-invading cells. The in-
vasion of MDA-MB-231 cells was found to be blocked by the compounds
tested, in a concentration as low as 0.5 μM of 1 and 2 μM of 5, and the
eﬀect size increased with higher concentrations (Fig. 4).
3.5. Gelatin zymography assay
In order to ﬁnd a possible explanation for the metastasis-inhibitory
eﬀect of compounds 1 and 5, the activities of released MMP-2 and
MMP-9 were determined by a gelatin zymography assay. The active
enzymes break down gelatin leaving a light patch on the blue back-
ground. None of our compounds exerted a signiﬁcant inﬂuence on the
activity of either MMP-2 or MMP-9 up to the concentrations of 2 μM (1)
or 4 μM (5), suggesting that the antimetastatic activity of the tested
compounds are independent of these enzymes (Fig. 5).
3.6. Western blot assay
The inhibition of focal adhesion kinase (FAK) and its phosphory-
lated form (pFAK) is another possible mechanism to block metastatic
processes. Therefore the changes elicited by the tested compounds in
the levels of proteins FAK and pFAK proteins were determined. Both
compounds 1 (0.5–2 μM) and 5 (1–4 μM) reduced the level of phospho-
Fig. 3. Eﬀects of compounds 1 and 5 on the migratory capacity of MDA-MB-231 cells (upper panels). The rates of the migration were evaluated after incubation for
24 h. Results are mean values ± SEM from three measurements *** indicates p < 0.001 as compared with the untreated control samples. Representative images of
the migrating cells in 0 and 24 h (lower panels).
Fig. 4. Eﬀects of compounds 1 and 5 on the cell-invasion
capacity of MDA-MB-231 cells (upper panels). Statistical
analyses of the percentage of invasive cells after incuba-
tion for 24 h with the test compounds. Results are mean
values ± SEM from three measurements. *, ** and ***
indicates p < 0.05, p < 0.01 and p < 0.001 as com-
pared with the untreated control samples, respectively.
Images from a visual ﬁeld of one representative experi-
ment (lower panels).
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FAK in a concentration-dependent manner, without exerting any action
on the total amount of FAK, indicating that the phosphorylation of FAK
protein is inhibited by the compounds tested (Fig. 6).
4. Discussion
An endogenous derivative of 17β-estradiol (E2), 2-methoxyestradiol
(2-ME) was discovered as the ﬁrst estrane analog with potent growth-
inhibitory eﬀect, but without binding to the estrogen receptor (ER)
(LaVallee et al., 2002). Since the possible mechanism of action,
pharmacokinetic properties, selectivity and toxicity of 2-ME have been
widely investigated, potential antiproliferative agents with an estrane
skeleton are a new focus of the research and development of anticancer
drug candidates (Kumar et al., 2016). Several studies have demon-
strated that the antitumor mechanism of action of 2-ME comprises
antiproliferative, antitubulin, antiangiogenic, antimetastatic and proa-
poptotic eﬀects (Minorics and Zupkó, 2018; Pribluda et al., 2000; Zhu
and Conney, 1998). Growth inhibition induced by 2-ME treatment in
numerous malignant cell lines, including lung, colon, breast, prostate,
eye, kidney, esophagus, stomach and pancreas cancers, as well as
Fig. 5. Eﬀects of compounds 1 and 5 on the activities of MMP-9 (pro-MMP-9, MMP-9 and its complex form) and MMP-2 (pro-MMP-2, MMP-2). Results are mean
values ± SEM from three measurements. The activities presented in graphs are expressed as the % of vehicle control group. None of the treatment-related diﬀerences
are signiﬁcant. A representative zymogram (right bottom panel).
Fig. 6. Eﬀects of compounds 1 and 5 on the expression of phosphorylated and total FAK protein in MDA-MB-231 cells (upper panels). Results are mean
values ± SEM from three measurements. *** indicates p < 0.001 as compared with the untreated control samples. Representative results of the Western blot
analysis (lower panels).
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tumors of the nervous system, melanoma, gynecologic malignancies,
angiosarcoma and carcinoma of the musculature, was conﬁrmed.
Amongst the examined cell lines, breast carcinoma was found to be the
most sensitive against 2-ME (Mueck and Seeger, 2010). It has been
reported that its antiproliferative action against various cancer cell lines
is mainly based on inducing blockade in the G2/M phase of cell cycle in
various cancer cell lines (Carothers et al., 2002; Li et al., 2004; Pribluda
et al., 2000; Qadan et al., 2001).
Treatment with 2-ME resulted in mitotic arrest in the prometaphase
through the intense early up-regulation of cyclin B1 and Cdc2 proteins
in both ER-positive and negative breast cancer cell lines. A close cor-
relation was observed between the time-dependent variations of the
prometaphase arrest and the level of the G2/M population. These re-
sults suggest not only the potent anti-microtubule eﬀect of 2-ME but
also demonstrate that this action is not inﬂuenced by the presence of
estrogen receptor (Choi and Zhu, 2012). Despite 2-ME was well-toler-
ated in clinical trials, both as monotherapy and in combination with
other anticancer agents, its activity was modest, even in a NanoCrystal
Dispersion (NCD) formulation possessing more advantageous bioavail-
ability (Harrison et al., 2011; Kumar et al., 2016; Matei et al., 2009).
Despite this failure these studies showed that the modiﬁcation of the
estrane skeleton may yield promising anticancer agents. The structure
of 2-ME has been recently utilized to design and synthesize a set of
quinazolinone-based microtubule disruptors indicating the unexploited
potency of the estrange skeleton as a base for innovative anticancer
agents (Dohle et al., 2018).
Natural 17β-estradiol has been recently demonstrated to bind to
DNA directly and that binding is not limited to the estrogen response
element but it can aﬀect random DNA sequences. This binding involves
the intercalation of the steroid between base pairs of DNA, forming
aromatic interactions with these base pairs (Hilder and Hodgkiss,
2017). These ﬁndings may serve as an explanation for the hormonal
receptor independent character of a wide range of estrogen-related
potential antiproliferative molecules including our present analogs.
Since the requirements of binding to the estrogen receptors are well-
established, it is also known that a methlyl substitution at C-3 by itself is
suﬃcient for the loss of the estrogenic activity (Anstead et al., 1997).
Another opportunity to conﬁgure estrogen derivatives with low re-
ceptor binding aﬃnities (RBA) is the speciﬁc substitution at C-16 with a
polar or large group, such as hydroxymethyl. The compounds we ex-
amined contain a benzyloxy function at C-3 and a hydroxymethyl at C-
16, therefore the lack of hormonal activity can be expected. This feature
of the isomers of 16-hydroxymethyl-3,17-estradiol analogs was con-
ﬁrmed by radioligand-binding assays (Tapolcsányi et al., 2002). Pre-
viously we have reported on the antiproliferative action of estradiol-
based compounds containing several distinct modiﬁcations at C-3 and
C-16. The 16-triazole compounds of the 13α-estrone series were found
to be eﬀective against seven diﬀerent cancer cell lines (Mernyák et al.,
2015). Furthermore, a set of 16-hydroxymethyl-3-methoxy- and 16-
hydroxymethyl-3-benzyloxy-13α-estradiol derivatives were demon-
strated to exert potent anticancer activity against several gynecological
cell lines (Kiss et al., 2018).
These previous accomplishments have encouraged us to continue
the experiments with estradiol-derivatives, leading to the examination
of the growth-inhibitory potential of a set of 16-hydroxymethyl-estra-
diols against various human adherent breast cancer cell lines.
Based on our data, the conﬁgurations of the substituents at positions
16–17 have a limited role in the agents' antiproliferative potency, while
the benzyloxy function with p-substituent at position C-3 enhance the
antiproliferative eﬀect. Concerning the antiproliferative activities of the
tested agents compound 5 proved to be the most potent and in terms of
acting on non-cancerous cells it was comparable with cisplatin, which is
currently used in breast cancer therapy protocols (Carey, 2015).
Although 5 and its precursor molecule 1 showed appreciable
growth-inhibitory eﬀects against all of the cell lines examined (MCF-7,
MDA-MB-231, MDA-MB-361, T47D), our primary purpose was to
characterize its eﬀects and mechanism of action against MDA-MB-231,
a triple-negative breast tumor cell line. In spite of the diﬀerent re-
ceptorial status of the utilized cancer cell lines the IC50 values de-
termined for a given agent were not crucially diﬀerent. The aim of our
study was to describe antiproliferative actions which are unrelated to
receptorial status and our experimental system was optimized for this
purpose. The medium contained phenol red which has some estrogenic
action and it was also supplemented with usual fetal bovine serum in-
stead of charcoal stripped fetal bovine serum which contains no re-
sidual steroids.
Performing cell cycle analyses by ﬂow cytometry revealed that
treatment with these agents caused G1 phase accumulation with sig-
niﬁcantly elevated apoptotic cell population. These results are in line
with previously described G1 blockades by estradiol-related compounds
such as two unsubstituted 16-oxime estrone analogues and oxadiazole
derivatives of estrone (Berényi et al., 2013; Mernyák et al., 2013).
Approximately 90% of human cancer deaths are related to cancer
metastases (Mehlen and Puisieux, 2006). This multi-step process in-
volves local migration and invasion of tumor cells into adjacent tissues,
entering into the vasculature, surviving and leaving the circulation
system, with subsequent proliferation in distant organs that leads to
colonization (Eger and Mikulits, 2005). Therefore, besides the cytotoxic
and apoptosis-inducing approaches currently utilized in oncotherapy,
innovative drugs with an antimetastatic capacity are eagerly needed to
control cancer-related mortality. Besides their antiproliferative activity,
the compounds tested in our experiments also inhibited cell migration
and invasion, the initial steps of metastatic spread. Moreover, this sig-
niﬁcant reduction in cell migration was observed at a sub-anti-
proliferative concentration as low as 0.25 μM, after treatment for 24 h.
The inhibitory action of compound 1 on cell invasion capacity proved
to be more pronounced as determined by the Boyden chamber assay.
The role of matrix metalloproteinases (MMPs), a family of zinc-de-
pendent endopeptidases have been extensively investigated, since their
expression and activity are increased in almost all human cancer
compared with normal tissue (Egeblad and Werb, 2002). The increased
expression of MMP-2 and MMP-9 at the mRNA level was demonstrated
in MDA-MB-231 cells compared to normal HS578Bst breast cells.
Moreover, high expression of MMP-2 and MMP-9 in cancerous breast
tissues has a close correlation with lymph node metastasis and tumor
staging (Li et al., 2017). Based on our results of the gelatin zymography
assay, none of the examined compounds inﬂuenced substantially the
level of MMP-2 and MMP-9, indicating that these metalloproteinases
are not crucially involved in the mechanism of action of 1 and 5.
Focal adhesion kinase (FAK) is expressed in most cell types and
tissues and has a complex function in various processes including cell
spreading, diﬀerentiation, cell cycle, migration and cell death. The
activation of FAK principally occurs via autophosphorylation on tyr-
osine 397 by clustering of integrins (McLean et al., 2005). Several
studies have demonstrated its role in the regulation of cell migration.
The up-regulation of FAK was reported in various cancer types, in-
cluding malignancy of the breast, and its elevated activity correlates
with metastatic spread and poor prognosis of the disease (Miyazaki
et al., 2003; Recher et al., 2004). In breast cancer, FAK overexpression
is regarded as an early event in tumorigenesis which precedes cell in-
vasion and metastasis in ductal carcinoma in situ (DCIS) (Lightfoot Jr.
et al., 2004). On the contrary, the lack of FAK-activity is reported to
result in poor cell migration in response to chemotactic and haptotactic
signals, while overexpression of FAK increases cell migration in Chinese
hamster ovary (CHO) cells (Parsons et al., 2000). Our present com-
pounds decreased the level of pFAK (Y397) in a concentration-depen-
dent manner, whereas total FAK level was unaﬀected, demonstrating
that the phosphorylation of the kinase enzyme was inhibited. These are
the ﬁrst reported estrogen-related compounds which proved to be ef-
fective in the inhibition of FAK phosphorylation.
In summary, our study revealed that 3-substituted C16-hydro-
xymethyl-estradiols are potent antiproliferative agents against breast
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cancer cell lines. In MDA-MB-231 triple-negative cell lines 2 test com-
pounds caused programmed cell death and G1 phase elevation.
Furthermore, the molecules signiﬁcantly and concentration-depen-
dently inhibited cell migration and invasion, as well as the phosphor-
ylation of focal adhesion kinase in sub-antiproliferative concentration.
These results indicate that modiﬁed estradiol-derivatives can be re-
garded as promising candidates in the design of new anticancer agents.
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